Corvus Pharmaceuticals Inc (CRVS) Receives $13.58 Average PT from Analysts
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has been given an average recommendation of “Buy” by the seven analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $13.58.
A number of analysts have commented on CRVS shares. Zacks Investment Research raised shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $8.75 target price for the company in a report on Wednesday, November 7th. Cowen reissued a “buy” rating on shares of Corvus Pharmaceuticals in a research report on Friday, November 2nd. BidaskClub cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 21st. Credit Suisse Group raised shares of Corvus Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $11.00 to $15.00 in a research report on Wednesday, August 15th. Finally, Wedbush reissued an “outperform” rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, August 8th.
CRVS traded down $0.26 during trading on Thursday, reaching $7.25. 94,491 shares of the company’s stock were exchanged, compared to its average volume of 71,815. Corvus Pharmaceuticals has a fifty-two week low of $6.81 and a fifty-two week high of $13.91. The firm has a market capitalization of $231.62 million, a PE ratio of -2.67 and a beta of -0.57.
Several hedge funds and other institutional investors have recently made changes to their positions in CRVS. BlackRock Inc. boosted its position in shares of Corvus Pharmaceuticals by 10.1% during the first quarter. BlackRock Inc. now owns 737,118 shares of the company’s stock worth $8,499,000 after purchasing an additional 67,461 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Corvus Pharmaceuticals by 112.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 134,436 shares of the company’s stock valued at $1,550,000 after acquiring an additional 71,300 shares in the last quarter. Millennium Management LLC lifted its position in Corvus Pharmaceuticals by 925.6% in the 1st quarter. Millennium Management LLC now owns 605,303 shares of the company’s stock valued at $6,979,000 after acquiring an additional 546,286 shares in the last quarter. Acadian Asset Management LLC lifted its position in Corvus Pharmaceuticals by 129.3% in the 2nd quarter. Acadian Asset Management LLC now owns 21,494 shares of the company’s stock valued at $236,000 after acquiring an additional 12,119 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at $147,000. 88.61% of the stock is currently owned by institutional investors.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
See Also: Stop Order
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.